Arena Pharmaceuticals

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Research, Financial management, Mirati Therapeutics, Medication, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, CFO, General counsel, Patient, Pharming, Strategic planning, Arena Pharmaceuticals, Acquisition, Bristol Myers Squibb, Drug, MBA, Marketing, Drug development, Access, Disorder, Corporate development

Aaron Ondrey joins Rocket as Chief Financial Officer, bringing more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions having held multiple finance leadership positions across the pharma and biotech industry.

Key Points: 
  • Aaron Ondrey joins Rocket as Chief Financial Officer, bringing more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions having held multiple finance leadership positions across the pharma and biotech industry.
  • Prior to Mirati, Mr. Ondrey also held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.
  • The key appointments within Rocket’s existing corporate leadership team are as follows:
    Kinnari Patel, Pharm.D., MBA, has been appointed President, Head of R&D and Chief Operating Officer.
  • J.D., has been appointed General Counsel & Chief Corporate Officer, and will lead Legal, Compliance, and Corporate Development.

Ropes & Gray Expands its Antitrust Team with Arrival of Jackie Grise

Retrieved on: 
Monday, March 18, 2024
Culture, Head, Amazon, Environment, Horizon Therapeutics, Ropes & Gray, Arena Pharmaceuticals, Sale, Acquisition, Woman, Intersect ENT, Lawyer, Therapy, Mastercard, Stent, PI, Amgen, Intersection, FTC

Jackie, a Chambers-ranked practitioner, brings more than 25 years of antitrust experience—and a strong understanding of government antitrust enforcement priorities—to Ropes & Gray's global client base.

Key Points: 
  • Jackie, a Chambers-ranked practitioner, brings more than 25 years of antitrust experience—and a strong understanding of government antitrust enforcement priorities—to Ropes & Gray's global client base.
  • She has successfully guided antitrust reviews in headline deals in which U.S. antitrust enforcers have issued "second requests."
  • Jackie expands Ropes & Gray's award-winning antitrust practice, which Chambers notes "offers top-flight representation across the full spectrum of antitrust matters," across industries where Ropes & Gray is a giant – private equity, asset management, health care, life sciences, and technology, among other key areas.
  • I am excited and proud to join the already elite, deep bench of antitrust lawyers on the team," said Jackie.

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, DSM-IV codes, Patient, Internal medicine, Therapy, UCB, Pathogenesis, Molecular biology, University, Arena Pharmaceuticals, Ascending cholangitis, Medication, Alza, Hospital, Massachusetts General Hospital, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer.
  • Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics.
  • In tandem with Dr. Quan’s appointment, Mirum announced the promotion of Peter Radovich to President and Chief Operating Officer.
  • I’m thrilled that she is joining at such an exciting time for Mirum, strengthening our team and leadership in rare disease,” said Chris Peetz, Chief Executive Officer at Mirum.

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Retrieved on: 
Monday, January 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Marketing, Arena, Pfizer, Autoimmune disease, GSK plc, Dermatology, Multimedia, Johnson & Johnson, Amgen, AstraZeneca, Child, Rheumatology, Arena Pharmaceuticals, Protocol, Trust, Lupus, CCO, University, Wellcome Trust, Doctor of Philosophy, Therapy, Senior, State, University College London, Great Ormond Street Hospital, Inflammation, Myositis, MBBS, Regeneron Pharmaceuticals, Growth, Mergers and acquisitions, Patient, State university system, Economics, Scleroderma, Management

Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company.

Key Points: 
  • Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company.
  • Mr. Lisicki and Dr. Nistala have successfully worked on or led in the development of multiple drugs within the auto-immune therapeutic area.
  • These executives position Zura Bio to deliver on the promise of their innovative medicines for patients in need of better clinical outcomes.
  • View the full release here: https://www.businesswire.com/news/home/20240108851979/en/
    “I am very pleased to welcome Rob and Kiran to Zura Bio as members of the Executive Team.

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Retrieved on: 
Thursday, December 7, 2023
Potential, Arena Pharmaceuticals, Therapy, Annual general meeting, Drawing, Interactive Brokers, Holding company

The initial meeting lacked a quorum, with insufficient votes to approve the reverse stock split proposal.

Key Points: 
  • The initial meeting lacked a quorum, with insufficient votes to approve the reverse stock split proposal.
  • The Board of Directors emphasizes the importance of this stockholders' vote, specifically urging a positive vote FOR the reverse stock split.
  • If you have previously cast your vote against the reverse stock split, we strongly recommend reconsidering your position and voting in favor of this proposal.
  • I encourage all shareholders to vote for the reverse stock split, particularly those who have voted against it.

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Retrieved on: 
Monday, October 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Genentech, LLP, Drug development, Abstract, Harvard University, Pfizer, Data management, Drug, Pharmacyclics, Arena Pharmaceuticals, Therapy, SMMT, Quality of life, Lasso, PwC, Knowledge, Amgen, Biogen, AbbVie, Athenahealth, CFO, Stonehill College, Faculty, Risk, Jazz Pharmaceuticals, University, Cancer, Jazz, Trust, Nektar, Immunotherapy, CMO, Biostatistics, Information technology, Alnylam Pharmaceuticals, MD Anderson Cancer Center, Public health, Regulatory affairs, Nektar Therapeutics, Sale, Senior, Doctor of Philosophy, Licensed practical nurse, ARIAD Pharmaceuticals, Growth, Hematology, Patient, Management, Nursing, Pharmacovigilance, Robert Maki

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.
  • “Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit.
  • “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.
  • I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”
    Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer.

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Monday, October 16, 2023
Janus, Incidence, Language, NYSE, Food, UC, JAK, Proctitis, HKEX, Pfizer, Safety, First Affiliated Hospital of Xinjiang Medical University, Disease, Arena Pharmaceuticals, Ulcerative colitis, FDA, Mount Everest, Clinical trial, Modulation, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, PFE, Pharmaceutical industry

SHANGHAI, Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • SHANGHAI, Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).
  • Everest is conducting a multi-center Phase 3 clinical trial of etrasimod in Asia and aims to file New Drug Application as soon as possible.
  • "Etrasimod's FDA approval marks an important milestone for moderately to severely active UC patients who need new treatments for this chronic condition.
  • Everest Medicines obtained exclusive rights from Arena to develop, manufacture and commercialize etrasimod in Greater China and South Korea in 2017.

Global Sustained Release Excipients Research Report 2023: Embracing the Future of Drug Delivery - The Growing Demand for Sustained-Release Excipients to 2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Medical Supplies, Health, Chemicals, Plastics, Medical Devices, Manufacturing, Pharmaceutical, Biotechnology, Sugar, Polymer, Wurster, Pan American Health Organization, Acquisition, Tuberculosis, Inflammation, Prevalence, API, Arena Pharmaceuticals, Cancer, Diabetes, WHO, World Health Organization, Gelatin, Growth, Mineral, Excipient, Chitosan, Pfizer, Pharmaceutical industry

The "Sustained Release Excipients Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sustained Release Excipients Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In a rapidly evolving pharmaceutical landscape, the quest for more advanced drug delivery mechanisms is paramount.
  • Their role becomes increasingly essential as the global population grapples with both acute and chronic diseases.
  • The countries covered in the sustained-release excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Adiso Therapeutics Expands Board of Directors with Appointment of Robert Lisicki

Retrieved on: 
Thursday, October 12, 2023
Acquisition, UC, Amgen, Regeneron Pharmaceuticals, Inflammation, Trial of the century, IBD, Strategic planning, State university system, BS, Inflammatory bowel disease, Arena Pharmaceuticals, Transgene (company), Ulcerative colitis, Therapy, Immunology, JNJ, Janssen Pharmaceuticals, State University of New York Upstate Medical University, Economics, Pfizer, MRP2, Patient, Neutrophil, Pharmaceutical industry, Circulatory system, Pain

CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.

Key Points: 
  • CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.
  • "The Adiso Board and I are very pleased to welcome Robert Lisicki.
  • Rob is an accomplished biopharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition," said Jason Dinges, Morningside Technology Advisory and Adiso Board Member.
  • Mr. Lisicki has nearly 30 years of experience in the pharma/biotech sector, most recently serving as Chief Executive Office and Board Member of InCarda Therapeutics.

Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

Retrieved on: 
Wednesday, October 4, 2023
Health, Biometrics, Other Health, Other Science, Research, Science, Pharmaceutical, University, Therapy, Regeneron Pharmaceuticals, Arena Pharmaceuticals, Quality of life, Orthostatic hypertension, Bristol Myers Squibb, MBA, SERA, Ulcerative colitis, Atrasentan, Patient, Sanofi, Biology, Jan Vansina, Chronic kidney disease, Safety, Pharmaceutical industry, Chinook

Nuvig Therapeutics, Inc. , a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.

Key Points: 
  • Nuvig Therapeutics, Inc. , a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.
  • He is passionate about improving the health and quality of life for patients,” said Julie Anne Smith, Chief Executive Officer of Nuvig Therapeutics.
  • I look forward to working with the high-caliber team at Nuvig to advance our clinical programs to maximize the therapeutic impact of this incredible opportunity in medicine.”
    Prior to Nuvig, Dr. Glicklich was the Chief Medical Officer at Chinook Therapeutics, where he focused on biologics and small molecules for rare, chronic kidney diseases.
  • Before working at Chinook, Dr. Glicklich was the Chief Medical Officer at Bird Rock Bio, focusing on monoclonal antibody development for inflammatory and fibrotic diseases.